Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Newbury Pharmaceuticals

1.52 SEK

-0.33 %

Less than 1K followers

NEWBRY

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.33 %
-27.86 %
-39.64 %
-40.59 %
-56.96 %
-55.18 %
-77.39 %
-
-87.98 %

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Read more
Market cap
46.05M SEK
Turnover
21.79K SEK
Revenue
31.58M
EBIT %
-69.57 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.1
2026

General meeting '26

21.1
2026

Interim report Q1'26

15.4
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Press release11/18/2025, 12:50 PM

Nordic Market Update

Newbury Pharmaceuticals
Regulatory press release11/11/2025, 12:15 PM

Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO

Newbury Pharmaceuticals
Regulatory press release10/29/2025, 7:00 AM

Newbury Pharmaceuticals year-end report September 2024 – August 2025

Newbury Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10/24/2025, 6:30 AM

Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury

Newbury Pharmaceuticals
Press release10/23/2025, 12:30 PM

Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury

Newbury Pharmaceuticals
Press release9/23/2025, 6:30 AM

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.

Newbury Pharmaceuticals
Press release8/11/2025, 8:00 AM

Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury

Newbury Pharmaceuticals
Regulatory press release7/9/2025, 6:00 AM

Newbury Pharmaceuticals interim report September 2024 – May 2025

Newbury Pharmaceuticals
Regulatory press release4/28/2025, 7:21 AM

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement

Newbury Pharmaceuticals
Press release4/16/2025, 11:30 AM

Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury

Newbury Pharmaceuticals
Regulatory press release4/9/2025, 6:00 AM

Newbury Pharmaceuticals interim report September 2024 – February 2025

Newbury Pharmaceuticals
Press release3/19/2025, 10:00 AM

Newbury Pharmaceuticals expands its portfolio with four new products

Newbury Pharmaceuticals
Press release3/14/2025, 7:30 AM

Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets

Newbury Pharmaceuticals
Press release1/24/2025, 9:00 AM

Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules

Newbury Pharmaceuticals
Regulatory press release1/24/2025, 7:00 AM

Newbury Pharmaceuticals interim report September 2024 – November 2024

Newbury Pharmaceuticals
Press release1/22/2025, 8:00 AM

Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets

Newbury Pharmaceuticals
Press release1/15/2025, 1:00 PM

Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray

Newbury Pharmaceuticals
Regulatory press release1/15/2025, 10:23 AM

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

Newbury Pharmaceuticals
Regulatory press release12/11/2024, 6:30 PM

Newbury Pharmaceuticals publishes its annual report for 2023/2024

Newbury Pharmaceuticals
Regulatory press release12/11/2024, 8:30 AM

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.